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Although assays for the measurement of tumour markers have been available for many years, their use has, until recently, tended to be restricted to a limited number of laboratories that are directly associated with Medical Oncology units. These laboratories have offcred assays for a small number of tumour markers using fairly basic, often in-house immunoassay methods.
Within the past five years, there have been two major advances in the area of tumour markers, both linked to the discovery and production of monoclonal antibodies. First, several new turnour markers have been isolated that offer the potential of improved clinical usefulness in an increasing number of tumour types. Secondly, This paper was prepared at the invitation of the Clinical Laboratory lnvesligalions Working Party of the Scientific Committee of the Association of Clinical Biochemists. but does not necessarily reflect their views.
Correspondence: Dr G H Beastall methodology, both {'or the ncw and the pre-existing tumour marker assays, has changed dramatically, and commercial systems have bcen produced which have simplified the steps involved to such an extent that these assays now fall within the scope of every Clinical Biochemistry laboratory. Accompanying these advances has been an increasing awareness of the role of tumour markers by many physicians and surgeons outside Medical Oncology units. such that the number of requests for tumour marker assays is growing rapidly.
In this article we attempt to review the role of established tuinour markcrs and to provide advice and guidelines to clinicians and clinical biochemists who are considering expanding into this area. For a review of the present role and potential of some of the newer tumour markers, the reader is rcferrcd to a previous article in this Journal.' 6 Brastall ct al.
WHAT IS A TUMOUR MARKER?
A tumour marker is ; 1 substance thc coiiccntration of which can be relatcd to the prcscnce or progress of a tumour. I t does not ncccssiirily have to be tumour-specific. but may be ;I substance secreted (into blood or serous fluids) o r cxpresscd (at the cell surface) in largcr quantities by malignant cells or their environs than by their normal counterparts. and may thus represent ;I rclative rather than an absolute ni;irkcr of malignancy. There nre two ways of assaying markers for solid tumours-by measuring the concentration in body fluids (usu;illy by immunoassay) o r by detecting the presence of the marker on the cell surface in paraffin sections. smciirs. o r fresh biopsy tissue. The Clinical Biochemistry laboratory is involved only in the first type o f assay. ' Tumour markers that are produced within the turnour. whether by malignant or stromal cclls. are said to be tumour-derived. whcrcas thosc markers produced by non-malignant cclls ;IS ii result ofdisturbance by the ttimour are said to be tumour-associated. This review will concentrate on tuinour-derived niarkers; readcrs arc referred elsewhere for a consideration of the metabolic manifestations of cancer.'
HOW IS THE USEFULNESS OF A TUMOUR MARKER ASSESSED!
Much of the early work on tumour markers was characterized by a lack of objective criteria for assessing the usefulness of a particular marker. Thus, the reported success of tumour markers in small studies of carefully selected patients were often not borne out in larger studies of less welldefined patients. In order to minimize these problems. two separate scoring systems have evolved which are now regarded as essential in any publication which aims to assess the clinical usefulness of a tumour marker assay. The first scoring system relates to the staging of the tumour being studied. Staging aims to classify tumours according to defined criteria. including size and the presence or absence of metastases. The definition of these criteria for each turnour type is clearly beyond the scope of this review, but the reader will appreciate how fundamental staging is if sensible comparative studies of tumour markers are to be performed. The second scoring system is the adoption of diagnostic specificity, sensitivity and predictive value as defined by Galen and Gambino.' Thus. the clinical usefulness of any tumour marker may be defined in terms of the following: It should be noted that the terms specificity and sensitivity used in this context do not relate to the use of those same terms in defining the pcrformance characteristics of assays, including tuinour marker assays. In the latter context. specificity relates to the lack of cross-reactants and sensitivity means minimum detection limits.
USE OF TUMOUR MARKERS (a) Screening for primary disease
With the discovery o f cach ncw ttimotir marker conies thc hopc that it will prove to have such cxccllcnt spcciticity and sensitivity that i t m a y bc uscd to diagnose pi-imary disease bc1i)l-e i t is suspected clinically. Such ;I marker would signilicanrly improvc the chances ofsucccssful therapy. since the rumour could bc tacklcd ;it an early stage in its evolution. often hcforc nicl;istascs Regrettably, thcrc ;ire only ;I very 1i . w turnour iiinrkcrs that exhibit sullicicnt specificity iind +ensitivity to ciiiiblc them to be uscd for screening. A rare cxamplc is plasma calcitonin. The best imniunoassays demonstrate clcvi~tcd pl;isni;i calcitonin concentralions in ;ill subjects with niedullary carcinoma of the thyroid.' and basal and/or stimulated concentrations o f calcitonin may be used to prcdict curly ttiinour growth in close family relutivcs and. where appropriate. allow prophylactic thyroidcctomy."
(b) Diagnosis of primary disease
The second use of ;I tumour marker is in helping to establish the diagnosis of malignancy in a patient with symptoms. preferably in the early stages of the evolution 01' the tumour. The extent to which ;I positive tumour marker result can be uscd to diagnose primary malignancy depcnds upon the specificity of the marker for that tumour. I t should be stressed that a negative tuinour marker result cannot be uscd to exclude have developed. primary malignancy except in tho very I'cw situations where ;I tutiiour marker has I O O ' h scnsittvily Ibr ;I specific t u m o u r type.
Same turnour markers arc thcmsclvcs hiologically active niolcculc~ (c.3. hormones) s o that syiiiptonis may he dircctly rclatcd to elevated tuniour marker concentrations. Other tumour markers are biologically inert. but the tinding of a high plasma concentration may be the first indication of an underlying malignancy in someone with non-specific symptoms. Commonly. tumour markers arc used in conjunction with radiology and tissue biopsy to establish the diagnosis.
(c) Prognosis
In ii limited number ofcases, the tumour marker concentration at the time of diagnosis may be used to predict the likely clinical outcome. To be of value in prognosis. the tumour marker concentration should correlate closely with tumour size and/or activity, so that a modest elevation means a sm;ill localized tumour, whilst a greater elevation suggests bulky disseminated malignancy or an aggressive turnour. Figure I shows the post-operative conccntrations of the tumour marker alphafetoprotein (AFP) in a 27-year-old nian diagnosed as having l ;i mulignant teratonia without clinical evidence of mctastasco. However. the tinding of AFP concentrations of > 10000 K U / L would indicate ii high chance of tumour recurrence and s o stress the need for intensive follow-up.'
(d) Monitoring therapy of primary disease
If tumour markers havc proved generally disappointing for the diagnosis of primary disease. then they havc bccomc well established a s ;in invaluable adjunct t o monitoring the cflicacy of therapy of primary disease. Thus, the plasma concentration ol'a particular tumour marker in a tumour marker positive patient may be used a s a very crude index of the size and/or activity of the lumottr. Effective therapy to reduce the size/ activity of the tumour. whether it be surgery, chemotherapy, radiotherapy or a combination of these. will result i n il corresponding FdII in the plasina concentration of the tumour marker. This is illustrated in Fig. I . where the very high AFP concentration one day after surgery is reduced by more than 50% seven days later. and continues to fall consistently until it is below the minimum detection limit of the assay on Day 74.
Koy phrases are often used to describe the effectiveness of therapy as judged by reductions in circulating concentrations of tumour markers. We define these key phrases as follows:
N o change marker docs not fall to < 50% of pretreatment concentration; Improvement marker falls to < SO% of pretreatment concentration; Response marker falls to < 10% of pretreatment conccntration: Complete response marker concentration falls to w i thin ti onin a I igna nc y reference value. Figure I demonstrates the value of regular monitoring of a turnour marker in the initial period following therapy of primary disease. Once the concentration of the tumour marker has s t l i b i l i d the frequency with which it is monitored may be reduced steadily, but monitoring should not cease altogether. The frequency of monitoring during therapy will be determined by many factors. including the nature of the primary tumour. the tumour marker that is being used together with its initial concentration, the therapy administered and the initial response to that therapy. Such decisions should be taken jointly by the physician and the Clinical Biochemist after reviewing all relevant information on each individual patient. Figure 1 also demonstrates one other advantage of regular monitoring of a turnour marker such as AFP, for the data available niay be uscd to calculate the half-life of AFP in plasma following surgery. The equation given below may be applied where t,/> = the half-life of AFP and t , is the difference in days between the sample with the AFP concentration on Day T and thc earlier sample taken on Day T,,. Application of this equation to the data in Fig. I yields a t,,: = 6 days, which is at the upper limit of the accepted half-life of AFP in normal subjects, thereby suggesting almost complete removal of the teratoma and a reasonably optimistic prognosis under the circumstanccs.
All the established tumour markers dcscribcd in this rcview may be used in the manner described for AFP in this patient, and it is probable that most, if not all, of the new tumour markers will have similar value in particular patients.
(e) Follow-up for early evidence of tumour recurrence
As cxpericnce with thc use and undcrstanding of tumour markers has grown. it has become apparent that one of the most valuable functions of a tumour marker is to provide an early indication of tumour recurrence. Thus, there is a great merit in continuing to monitor a patient who was turnour marker positive, even after the concentration of that marker has stabilizcd. normalized or becomc undetcctable following successful therapy. A further significant rise in the conccntration of thc tumour niarkcr may provide the first evidencc of recurrencc and so allow for prompt and effective second line therapy. This general principle may again be illustrated by reference to Fig. I . where a rise in AFP o n Days 151 and 157. confirmed on Day 162 following surgery, provided the first evidencc of recurrent teratoma and so prompted thc course of chemotherapy given o n Day 170. The value of early evidence of tumour recurrence is greatest for those tumour types where clinical evidence of recurrence is most diEcult to obtain. It should be stressed that a clinician will rarely act on the basis of a single positive tumour marker result, and it is esscntial that the laboratory can provide rapid confirmation similar to that shown in Fig. I .
One real problem for the Clinical Biochemist is to determine the appropriate action limits for the tumour marker assay so as to ensure that a significant rise has occurred which may he interpreted with confidence as tumour recurrence. There are two main factors to be considered in determining these action limits. The first is a detailed knowledge of the baseline security and inter-assay imprecision of the tumour marker assay at an analyte concentration close to the likely action limit. The second factor is the appreciation that arbitrary 'normal values' have little or no relevance in this situation, where the key parameter is the change in concentration that a patient shows from his or her own recent baseline. Further reference to Fig. I will demonstrate this point, for the rises in AFP on Days 151 (7KU/L) and 157 (12KU/L) are still within the upper limit of I5KU/L found in normal subjects. If the result of 7 K U / L on Day 15 1 had been dismissed as 'normal' then several weeks may have elapsed before AFP was monitored again. As Fig. 1 proves, confirmation of a rising level on Day I57 was quickly followed by a rise above the 'normal range' by Day 162 (20 KU/L). The issue of action limits for tumour marker assays is part of the wider topic of analytical goals, which has recentl) been reviewed .'
ASSAYS FOR T U M O U R MARKERS
Long established chemical methods niay bc uscd to assay a small proportion of tuniour niarkcrs (e . g . nor-met ad rma li ne. 5 -h y d rox y i ndo I c ;icc t ic acid), and assays of enzyiiic activity may bc tiscd for other markers (e.g. prostatic acid phosphatase). Howcvcr, most of thc hormonc tumour markers and the new tumour markcrs are based on inimunoassay-ofleii employing monoclonal antibodics. and in sonic casts with non-isotopic signal detection systems.
Modern commercially availablc i m m t i n oassays for tumour niarkcrs arc technically w r y simple to use and capable of cxccllcnt prccision. However. these factors should n o t mask the problems that can be encountered in thc application of the assays to patient populations. Appropriate quality control pools should be run with each assay to cover the key action points, the full working rangc of the standard curve and also the rangc of conccntrations encountered in routine practice. This selection of quality control pools is vital, and it may be necessary to prepare a single donor (HIV negative) tumour marker 'high' quality control pool that is diluted in each assay. Wherever possible UK laboratories should register their tumour marker assays with a UK External Quality Assessment Scheme, although relatively few such schemes exist for tumour markers at present." Users should also take care when comparing results with other methods for the same tumour marker, for it is common for different methods to use antibodies with different characteristics and standards of different composition and potency. For these reasons, laboratories should endeavour to establish thcir own rcfcrence values rather than adopt those published by another group.
The very wide range of tumour marker concentrations found in clinical practice should also alert analysts to the potential for carry-over problems which are a real risk. especially if automatcd sample processors arc used. Care must also be taken to cnsure that high concentration samples dilutc in parallel with thc standard curve a n d that adequate volumes of suitable dilucnt are available for this purpose. The highdose hook effect" is a potential problcin for tuniour marker assays based o n two-site imniunonietric methods. Artiticially low results may be obtained in samples containing very high concentrations of certain tumour markers unless the cxtent of the assay plateau is known and appropriate sample dilutions are performud. For example. in Glasgow all ncw patients and all known high AFP patients have scrum specimens analyscd neat and at ii 1/1000 dilution to eliminate the risk of the high-dose hook in the Glasgow ;issay."' Onc final note of warning about the new two-sitc inmunometric tumour marker assays is the risk that the presence of anti-specics antibodies in the patient's serum may lead to artcfactually high results." Clearly, an artcfactually clcvated tumour inarkcr result could have serious conscqucnces. for clinical intcrvention in oncology tends to be rapid.
Commercial assays for tumour markers are expensive. with reagent costs in the range EI-E3 per sample. Such costs mean that the Clinical Biochemist has a responsiility to ensure that the assays are used only in situations likely to generate clinically valuable information. Thus, requests for tumour marker assays should be turned round within one working week, and laboratories that d o not have the workload or the staff resources to meet this criterion should seriously consider sending their specimens to a Regional Centre. Clinical Biochemists should liaise closely with the physicians and surgeons using their tumour marker assays. The use of these assays for diagnosis of primary disease should be limited to those situations where there is a high probability of a tumour marker positive result-requests for a panel of markers in a patient who 'might have a tumour' should be discouraged.
Paradoxically, the Clinical Biochemist may have to encourage the clinician to send more frequent specimens during followup after treatment of primary disease to minimize the chance of a delay of detecting recurrent disease in tumour marker positive patients.
BRIEF REVIEW OF ESTABLISHED TUMOUR MARKERS
Many different compounds could be considered as tumour-derived markers of malignancy, but a comprehensive review of all such compounds is beyond the scope of this paper, which deals only with those markers that have gained general acceptance in clinical practice or which promise to d o d o within the next few years ( Table 1) . Hormone receptors have not been included in this review, nor has thc PTH-related peptidc now thought to be responsible for much of the hypercalcaemia of malignancy.
Enzymes
Abnormality of plasma enzyme activity is a common finding in malignancy. In general, however, the enzymes in such circumstances are tumour-associated rather than tumour-derived, and so beyond the scope of this article. Only one enzyme will be considered in detail in this review --prostatic acid phosphatase (PAP). Readers are referred elsewhere for a recent review of the roles of placental alkaline phosphatase and neurone specific enolase as tumour markers.'
Hormones
A wide variety of hormone-secreting malignant tumours are known, although none of them occurs commonly. Hormones produced by tumours are referred to as eutopic if they arc appropriate to the tissue of origin. Hormones as tumour markcrs are usually dealt with in endocrine or gastroenterology texts, and so only a few general remarks will be included here.
Peripheral hormone conccntrations serve as good markers of the secrctory capacity of the tumour. although they provide no indication of the extent of non-secretory elements. Measurement of the eutopic hormone concentration is essential to the diagnosis of the malignancy since endocrine tumours tend to be small. with clinical symptoms of hormonc excess occurring bcfore the tumour is palpable or visible with basic radiological techniques. The sensitivity of eutopic hormones as tumour markers approaches 100%. but specificity is much lower and depends on cut-off valucs. because the hormones are present in all subjects.
The diagnosis of some eutopic hormone secreting tumours relies on the mcasurenicnt of hormone metabolitcs in urine rather than on thc plasma concentration of the hormone itself. Thus, phaeochromocytoma is diagnosed by measuring the urinary catecholamine metabolites vanillyl mandelic acid (VMA) or normetadrenaline (NMA), and carcinoid tumours are diagnosed by measurement of the major urinary metabolite of serotonin, 5-hydroxyindoleacetic acid (5-HIAA).
Hormones have short half-lives in plasma, and so a rapid fall in the eutopic hormone concentration is good evidence of successful therapy. Monitoring the effectiveness of therapy and the provision of carly evidence of recurrcnce is complicated by the normal production of hormone from any non-malignant tissue remaining after therapy.
Hormone secretion is a characteristic of APUD (amine precursor uptake and decdrboxylation) tumours, which are derived from tissue of neuroectodermal origin. Examples of APUD tumours which may be malignant include insulinoma, gastrinoma, phaeochromocytoma, neuroblastoma, medullary carinoma of the thyroid and carcinoid turnours. This common origin of many hormone secrcting tumours explains the existcnce of the pleuriglandular syndromes known as multiple cndocrinc ncoplasia, in which one patient may havc two. three or even more co-existent endocrine turnours.'* The APUD cell is also the source of ectopic hormone secretion, in which a tissue secretes a hormone not normally associated with it. Thc classical cxamplc of an ectopic hormonc is the ACTH secreted by a proportion of oat ccll citrcinoinas of thc rcspiratory tract. I n thcsc circumstances. ACTH has liniitcd usc as a tumour marker. for its concentration in plasma docs not corrclate with tumour mass. and thc prognosis is so poor that thc use of any tumour markcr is unlikely t o affect thc clinical outconic oncc thc accompanying hypcrcortiscdacmia has bccn minimized. Other examplcs of ectopic hormonc sccrction arc lcss well dctincd."
Paraproteins
Paraprotcins arc monoclonal immunoglobulins dcrivcd from B-cells. Thcy are found in thc plasma and/or urine o f almost all patients with malignant myeloma, in patients with other B-ccll malignancies, in patients with non-lymphoid tumours and in certain autoimmune conditions. Consequently, the sensitivity of paraprotcin measurement is very high ( 9 8 %~) for the diagnosis of malignant myeloma' although the specificity is significantly less good (61 "h).
Sevcral diffcrent classes of immunoglobulin occur in malignant myeloma, and thcir mcasurcmcnt and electrophoretic characterildtion is cssential to the diagnosis. The IgG and IgA sccreting myelomas arc the most common of thosc with a normal heavy to light chain ratio. hut myelomas secreting a preponderance of light chains are also quite common -appearing in the urinc as Bence Jones protein.
Paraprotcins scrvc as cxccllcnt tumour markcrs because their conccntration in plasma correlates wcll with tumour bulk. so much so that remission of malignant myeloma is defined in terms of reduction of initial paraprotein concentration. However, the long-term survival of a patient cannot be predicted. cither from the initial paraprotein concentration or from its ratc of Fdll following chemotherapy. The severity of symptoms and haemoglobin and urea conccntrations are better prognostic indices.I5
A full review of the laboratory investigation of paraproteinaemia has rccently been published.'"
Carcinoembryonic antigen
Carcinoembryonic antigen (CEA) was first described in 1965," since which time it has attracted considerable attention as a tumour marker. CEA is not a single entity but a family of related glycoproteins. Most normal persons have detectable circulating CEA concentrations. although the distribution is non-Gaussian and approximates to log-normal.'" This factor, combined with differences in methodology and poor spccificity (see below), have led to the lack of a consensus upper limit of the reference value, with a range from 2.5-20pg/L'q (75-600U/L, MRC 73/601) and to a recommendation that laboratories should obtain their own referencc data. "
A.s.vuy.s. Radioimmunoassays
based on polyclonal antisera have been available for several ycars.'" These antisera were raised against different CEA preparations, and so it is not perhaps surprising that they have shown different performance characteristics when applied to clinical studies. Recently, there has been a large increase in assay methods, especially immunometric methods based on monoclonal antibodies and employing either isotopic or a variety of non-isotopic labels. It is of note that the antigenic determinants of most monoclonal antibodies to CEA are the carbohydrate side chains rather than the protein backbone of the molecule. Modern CEA assays are capable of inter-assay coefficients of variation of 7-10%; it remains to be seen how well results correlate between the new generation of methods.
Spcificity. Serum CEA concentrations may be higher in men than in women, and increased by heavy smoking. CEA Concentrations are modcstly elevated in numerous nonmalignant conditions, most notably liver diseases such as cirrhosis or obstructive jaundice, pancreatitis. diverticulitis and inflammatory bowel discasc. fibrocystic breast disease and renal Failure." Thus, the specificity of a CEA assay will depend upon the population studied, the method and the assay cut-off adopted. Typical specificity figures of 85% have been reported at a cut-off of 7.5pg/L and 95% at 5pg/L." Scvuilivity. The sensitivity of CEA for the diagnosis of malignancy in population screening or in subjccts considered at risk has been studied exhaustively. At a cut-off point of 2.5pg/L, sensitivity for colorectal cancer has been reported to vary from 30-85%, being higher in symptomatic than asymptomatic patients.'" Similar figures have been publishcd for other gastrointestinal cancers (stomach, pancreas and liver), although the sensitivity is somewhat less for cancers of lung, breast, prostate and the female reproductive tract.2' Clinicul value. CEA measurement should not be performed in population screening for cancer," nor is the measurement of the glycoprotein recommended as the sole diagnostic tool for the investigation of patients at risk for colorectal carcinoma, although it may have some value as an adjunct to other tests," including some of the new tumour marker^.?^ A very high pre-treatment concentration of CEA suggests a poor prognosis, but there is still little evidence that this knowledge adds to that available from clinical staging or assists with patient management. ' CEA concentrations in serum correlate poorly with tumour bulk,? thus limiting the usefulness of the test in monitoring the response to therapy. However. a falling CEA concentration is generally indicative of tumour regression, and this is certainly the case for colorectal car~inorna.'~ Rising CEA concentrations may be used as an index of tumour recurrence-perhaps the only such index available, and it is in this area that CEA measurement has its greatest value. Regrettably. there is very little evidence that early knowledge of tumour recurrence has any dramatic effect on improving the clinical outcomc following procedures such as secondlook surgery for colorectal carcinoma, or radiotherapy/chemotherapy for tumours of various origins.'' Alphafetoprotein Alphafetoprotein (AFP), which was first isolated in 1956.'" is an oncofetal glycoprotein (MW 70000 daltons) which shows 30% structural homology with albumin. The primary structure of human AFP and its mRNA have been r e p~r t e d .~' As many as eight forms of A F P have been observed in human fetal serum:" the hetcrogcneity being explained by variations in carbohydrate content.
In normal physiology, AFP is made by human yolk sac cells and in later embryonic growth by the fetal liver, which then switches to albumin synthesis as it matures. 29 Consequently, material serum AFP concentrations alter in a consistent manner with increasing gestation. In the UK, almost all pregnancies are screened by measurement of maternal serum AFP between 14 and 18 weeks of gestation for evidence of fetal neural tube defects (relatively elevated AFP)30 and/or Down's syndrome (relatively low AFP)." As a tumour marker, AFP has applications in germ cell tumours, in primary liver carcinoma in adults and hepatoblastomas in children, and it is also occasionally elevated in cancer of the gastrointestinal tract Assays. Early assays for AFP were radioimmunoassays specifically targeted for maternal screening. A large number of such assays were developed and refined to the extent that the geometric coefficient of variation in the UK EQAS is 8-9%.'* More recently, two-sitc immunometric assays have been introduced, cmploying either radioactive labels'" or a variety of non-isotopic label^.^' These new assays arc likely to perform with precision at least as good as the RIAs but with a much wider working range, making them more applicable to screening for Down's syndrome and well suited for covering the range of values seen as a tumour marker (Fig. I) .
Specificity. Although AFP may be detected in most serum samples, it is only during pregnancy and the first year of life that relatively high concentrations occur in normal physiology. Consequently, the choice of appropriate cut-offs allows excellent specificity, and in one study only 0.3% of elevated A F P results occurred above a cut-off of 40pg/L (40 KU/L) in non-pregnant adults with non-hepatic benign lesions," although specificity docs appear to be assay dependent.'4 Modest elevations of AFP up to 100 KU/L occur in about 20% of patients with hepatitis, cirrhosis, biliary tract obstruction, or alcoholic liver disease."
Sensitivity. The sensitivity of AFP as a marker of hepatocellular carcinoma (hepatoma) is in the range 60-80%." In non-seminomatous germ cell tcsticular tumour the sensitivity of AFP alone is 50-70Y0,',~~ although this can increase to more than 90% when combined with measurement of human chorionic gonadotrophin (HCG).'b The proportion of patients with raised AFP is related to clinical stage, and serum AFP and HCG concentrations are higher when bulky metastases are present." The sensitivity of A F P in various gastrointestinal carcinomas is in the range 5-23%, and it is below 10% in bronchogenic carcinoma." Clinical value. In hepatoma, the measurement of AFP as a tumour marker is of value in diagnosis. The sensitivity of the system does not encourage general population screening in the UK where the incidence of hepatoma is relatively low, although such screening can be justified in high incidence populations as found in parts of China. In the UK, however, selective screening is justified in high risk groups such as patients with cirrhosis, hcpatitis or haemochromatosis." AFP is the best tumour marker for monitoring thc response to thcrapy (usually chemotherapy) of hcpatoma.
In non-seminomatous germ cell tcsticular tumours, the combined use of AFP and HCG as tumour markers is now established; thcir presence can be correlated with the stage of the disease, albeit not perfectly,'" and so they are useful in reducing clinical staging errors." The initial concentrations of these two markers arc also of great value in predicting the p r o g n~s i s ;~~ for example, patients with HCG concentrations below 50oo01U/L and AFT below 500KU/L showed a 96% survival, in contrast to only a 56% survival in patients presenting with tumour markers at high concentrations.'" Such statistics stress the benefits of mcticulous thcrapy and monitoring, and a strong case has bcen made for a National Registcr of all patients with nonseminomatous germ cell tumours and those with seminomas who are HCG positivc. Consistent thcrapy and rapid monitoring of rcgistcrcd patients in a small number of specialist centrcs, using economical assays, should ensure maximum patient bcncfit for minimum cost.'"
Human chorionic gonadotrophin
Human chorionic gonadotrophin (HCG) is a glycoprotcin composcd of two subunits-an 2subunit ( M W 14500 daltons) which is idcntical to the z-subunit of the three pituitary hormones LH, FSH and TSH. and a /]-subunit (MW 22000 daltons) which is distinct from the /hubunits of FSH and TSH, hut which shows considerahlc homology with the /hubunit of LH over thc first 75% of its amino acid scquencc. The carbohydratc contcnt of HCG is variablc. but it can account for up to 30% of thc m o l~c u l c .~' HCG is produccd by the normal placenta, and plasma lcvels rise rapidly from shortly after implantation to reach maximum concentration during the eighth week of gcstation.' This rapid rise in plasma and urinary HCG has long bcen the basis of thc test to confirm pregnancy. and recent improvemcnts to mcthods of mcasuring HCG mcan that confirmation is now possiblc before a missed menstrual period. Rapid tests for the measurement of HCG are especially useful in the diagnosis of ectopic prcgnancy. A raiscd plasma or urinary HCG concentration at any time other than pregnancy suggests the presence of trophoblastic tissuc and forms the basis of the use of HCG as a tumour marker.' Assays. Early rddioimmunoassays for HCG showed an equimolar cross-reaction with LH which limited the specificity of their use as turnour markers in ovulating women and women past the menopause. Cross-reactivity with LH has been eliminated by raising antisera to the 25% of the HCG /]-subunit that is not found in LH -a process that has been aided considerably by thc ability to produce monoclonal antibodies which are used in immunometric assays. The clinical biochemist now has a huge choice of P-HCG assays with varying incubation times and either isotopic or a wide variety of non-isotopic labcls." In gcncral, rapid assays arc best suited for the diagnosis of pregnancy, whilst thosc with the lowest minimum detection limit are of greatest value as tumour marker assays. These latter assays are capable of inter-assay imprecision of better than 10% CV. Spc,c;ficit.y. The wide variety of available methods for HCG, the standard against which they are calibrated, and the extent to which they cross-react with LH and the free a-and 8subunits of HCG mean that there is no consensus as to the upper limit of a reference value for serum HCG for non-pregnant normal subjects. Staff in individual laboratories must not adopt a refcrence value from elsewhere, cspecially a centre using a different method, since this could cause a significant number of false positives or false negatives. Purely as a guide, therefore. the specificity of one assay calibrated against the Second International Standard for HCG has been reported as 83% using a cut-off of 5 IU/L.43
Sensirivity. With appropriate cut-off limits, 8-HCG concentrations in serum or urine are elcvated in 100% of cases of choriocarcinoma." The secretion of free subunits as well as intact HCG means the assay used and the cut-off adopted will influence the sensitivity of HCG as a marker of other tumour types. However, it is gencrally agreed that HCG is elevated in 40-76% of cases of non-scminomatous germ cell testicular c a r c i n~m a , ?~' . '~~~ although this figure is improved significantly by the simultaneous measurment of AFP and other markers such as lactate d e h y d r~g e n a s e .~~ Elevated plasma concentrations of HCG are found in 1&37% of patients with seminomas, presumably secreted by giant syncytial cells,2 but the sensitivity of HCG for non-trophoblastic tumours is only 11% or less." Clinical value. The measurement of plasma or urinary H C G has a proven role in the diagnosis and management of choriocarcinoma, which occurs in 5-10% of women who have a preg-nancy associated with hydatidiform mole.46 HCG concentrations in serum correlate well with tumour mass and allows for the detection of as few as 10' cells (1 mg of tissue)" which makes it the most sensitive test of any human tumour. Furthermore, the existence of a high risk group makes HCG measurement the ideal screening test for choriocarcinoma, and since 1973 all women in the UK who have a molar pregnancy enter a register which permits their follow-up at a specialist centre. Rising or grossly elevated 1-HCG either 1-2 months after evacuation of a molar pregnancy or in persistent uterine bleeding 4-6 months after evacuation are indications for chemotherapy, as is an unexpected rise in b-HCG at some later date. As a result, death from trophoblastic tumour after a mole is now very rare. 46 The value of HCG, when combined with AFP, in non-seminomatous germ cell testicular tumours has already been considered. There is a strong case for these patients and also for HCG-positive seminoma patients to be entered into a register analogous to that described for choriocarcinoma.4'' The clinical value of HCG in other tumours is restricted to monitoring therapy and predicting recurrence in those few patients who are tumour marker positive.
Prostatic acid phosphatase
Prostatic acid phosphatase (PAP) (EC 3.1.3.2) is an isoenzyme of orthophosphoric-monoester phosphohydrolase (PI 44-5.5). 48 Acid phosphatase has been known to be associated with prostatic cancer for 50 and its role as a tumour marker followed the observations that the enzyme activity in serum generally increases as the disease progresses.
Assays. Attempts to increase the specificity of the assay for the prostatic enzyme have led to a number of methodological improvements over the years, including tartrate inhibition of the prostatic acid phosphatase" and the selection of substrates such as thymophthalein monophosphate.5' Such methods that measure the activity of the enzyme are rapid, inexpensive, simple to perform and capable of inter-assay precision of better than 8% CV. However, the activity of PAP in serum is relatively labile.
Immunoassay methods for measuring the prostatic isoenzyme were introduced more than 10 years agoS2 in the hope that both the specificity and sensitivity of PAP as a tumour marker for prostatic carcinoma would improve. There are now many immunoassay systems available based both on saturation and immunometric assay principles and employing both isotopic and a variety of non-isotopic labels. All these methods are capable of inter-assay precision of better than 10% CV, but there are marked difference in their minimum detection limit and the uppcr limit of the reference value.48
Specificity. The wide choice of assays available for measuring PAP and the different units used to express enzyme activity have led to much confusion, and no consensus exists even amongst immunoassays as to the upper limit of a reference value for normal Under these circumstances, it is not surprising that specificity for prostatic carcinoma varies, and figures of 74-98% have been reported for the enzyme activity assays4R and 80-95% for the immunoassays.5' Sensitivity. The sensitivity of PAP as a marker of prostatic carcinoma has been determined on numerous occasions using several different assays methods. In summary. the sensitivity is usually in the range 8-30% for intracapsular lesions (Stage although there are two reports of 75 and 79% using i m m u n o a~s a y s~~~" which have not been confirmed. The sensitivity rises progressively with increasing disease severity, and is 66-95% in patients with distant metastases (Stage IV).48. 55 In general, immunoassay methods suggest modestly better predictive values than enzyme activity assays4* Clinical valur. The low sensitivity of PAP assays for Stage I prostatic carcinoma in the general male population makes screening for the disease a non-starter. Indeed, it has been calculated that the predictive value of a positive result could be as low as 0.41%.' PAP measurement contributes little to staging of the disease. 48 The main value of PAP measurement over many years has been in monitoring the response to therapy and providing early evidence of tumour p r o g r e s~i o n .~~ In this respect PAP has been more useful than many of the tumour markers discussed elsewhere in this review, but the recent advent of prostate-specific antigen (PSA) suggests that the tumour marker of choice for prostatic carcinoma is PSA rather than PAP (see below).
The choice of assay for laboratories that continue to offer PAP measurement lies between the cheap and convenient enzyme activity assay and the more topical and marginally more useful immunoassay-there is little to choose between them.
Prostate specific antigen
Prostate specific antigen (PSA) is a single chain glycoprotein of molecular weight 34 000 daltons that contains 7% carbohydrate by weight."' PSA lacks acid phosphatase enzyme activity, and is immunologically and biologically distinct from PAP." As its name implies, PSA is confined to the prostatic acinar cells and ductal epithelium, and is located in normal prostate. in benign prostatic hypertrophy (BPH) and in primary and metastatic prostatic carcinoma.5n AS.WJJ~S. Hybritech Inc. markets two assays for PSA based on the same combination of monoclonal antibodies. The TANDEM"'-R PSA immunoradiometric assay has been widely adoptcd: it has a minimum detection limit of 0.1 5 pg/L and inter-assay coefficients of variation of better than 6430/0." Similar performance characteristics are obtained from the Hybritcch Inc. immunoenzymatic assay. The most widely used radioimmunoassay is a Pros-Check'M PSA (Yang Lab Inc., Bellcvue, USA). This assay is slightly less precise and gives results significantly different from the Hybritech Specificitj. PSA is detectable in the serum of almost all men; it tends to increase with age and clearly rises in men with clinical evidence of BPH. Thus, the specificity or PSA as a turnour marker depends on the cut-offs used and the age of the subjects studied. In one mullicentre study of apparently normal subjects, all women. 99% of men aged < 40 years and 97% of men > 40 years had PSA concentrations < 4pg/L. The cut-off had to bc raised to lOpg/L to achicve a specificity of 100% in these subjects. In the same study, however, 20% of men with proven BPH had PSA levels > 4 pg/L and 2 % > I0 pg/L.5y Other series have reported similar Sensitivity. Using a cut-off of 4pg/L, serum PSA was elevated in 67% of men with StageA prostatic carcinoma and the sensitivity rose progressively to 88% in StageD. Overall, PSA was increased in 81% of cases. Corresponding sensitivities at a cut-off of lOpg/L were 30% in Stage A; 79% in Stage D; 66% overall. PSA was modestly elevated (4-1Opg/L) in only 5% of other malignancies; figures that could be explained by coincident preclinical BPH.59 Other series have reported broadly similar sensitivities.bUd4 ('linicd vcrlu~. The overlap in serum PSA values between men with BPH and those with prostatic carcinoma, coupled with the almost univcrsal prescncc of BPH in men aged over 55 ycars, means that PSA is of no value for population screening for prostatic carcinoma. Thus, with a cut-off limit of 4pg/L. the sensitivity of PSA for StagcA or B cancer is 65%. the predictive value of a positive result is only 27%. Raising thc cut-off limit to IOpg/L increases the predictive value of a positive rcsult to 65% but reduces the sensitivity to a nicrc 41u/~.h'
There is now wide acccptance that PSA is the tumour marker of choice for the investigation and monitoring of men suspected of having prostatic carcinoma. In a series of comparisons with PAP, the sensitivity of PSA was twice that of PAP. and the diffcrcnce was particuarly pronounced in thc early stages of the disease.s'~h'M Claims have been made that PSA is useful in staging the disease." PSA is also superior to PAP in monitoring the response to therapy; in one large series serial PSA reflected stable disease or predicted progressive disease with a sensitivity of 9 3 O h and a specificity of %%, compared to a sensitivity of 57% and a specificity of 96% for PAP." Other reports confirm this superiority.h',6h
In conclusion, there is convincing evidence for the use of PSA assays in those centres involved in the investigation of prostatic carcinoma. The balance of evidence indicates that PSA is superior to PAP, and there appears to be little benefit in offering both markers.
CONCI.USIONS
A 'perfect' tumour marker could be used in five differcnt ways: for population screening, for the diagnosis of malignancy, as a prognostic indicator, for monitoring therapy, and for followup for early evidence of recurrence. In order to achieve 'perfect' status a tumour marker would require total negativity in healthy subjects ( I 00% specificity), total positivity for a single tumour type (100% sensitivity), and close correlation between plasma tumour marker concentration and tumour size.
The advent of monoclonal antibodies has had a dramatic impact in oncology, where new tumour markers have been discovered and assay methods for all tumour markers have been improved and developed commercially. Analytical performance of these new methods is potentially as good as that of the best immunoassays for other analytes, but problems of standardization and a lack of External Quality Assessment Schemes makes comparison of different assay and different centres difficult. In many cases the development of a new assay method has preceded investigation of the clinical value of a tumour marker and much of the current activity in oncology centres around these evaluations. It is important, therefore, to distinguish between the established role of a tumour marker and its potential role as suggested by recent research. In order to make this distinction, Table 2 has been constructed to summarize those clinical situations in which the established tumour markers may be used.
It is clear from Table2 that very few tumour markers approach the 'perfect' status outlined above; only HCG has an established role for choriocarcinoma in all five possible applications, although it should be appreciated that even in this situation screening is justified only in a high risk population and choriocarcinoma is far from At present, the main clinical application for the other tumour markers is in the monitoring of therapy. Thus, the treatment of many tumours can now be monitored more efficiently and more economically by measuring circulating markers than by other methods. Unfortunately, many markers are mostly useful in paticnts with tumours that cannot be cured by current chemotherpay, and so the use of the markers cannot be considered mandatory in the same way that it is in patients with curable trophoblastic or germ-cell tumours. The emphasis of this paragraph may appear disappointing, but rapid advances are being made in oncology, and additions to Table2 are likely during thc next few years.
Two main areas of advance may be anticipated. First, tumour markers will be used increasingly as prognostic indicators to identify those patients at highest risk of relapse and likely to benefit from additional treatment such as neoadjuvant chemotherapy. Secondly, advances in the treatment of the most resistant tumours of breast, lung and colon will improve the prospects of affected patients and so increase the value of tumour markers for monitoring and for follow-UP.
The Clinical Biochemist may have a dilemma in deciding which. if any, tumour marker assays to include in the laboratory repertoire. It is being recognized increasingly that the most promising results of cancer treatment are obtained by specialist oncology units, and this realization has led to increased centralization of oncology services. Therefore, the Clinical Biochemist should provide tumour marker back-up appropriate to the local oncology service, either directly from his or her laboratory or indirectly from a Regional Laboratory.
